drugset / Trial / NCT00237900

Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer

NCT00237900

Phase 1/2 Terminated 34 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess safety, efficacy and explorative objectives of gefitinib in combination with chemoradiation in resectable gastric cancer

Timeline

Start
2003-07
Primary completion
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule
Background Leucovorin Small molecule
Background fluorouracil Small molecule